176 related articles for article (PubMed ID: 35333526)
1. Structure-Based Discovery and Optimization of Furo[3,2-
Li J; Zhang C; Xu H; Wang C; Dong R; Shen H; Zhuang X; Chen X; Li Q; Lu J; Zhang M; Wu X; Loomes KM; Zhou Y; Zhang Y; Liu J; Xu Y
J Med Chem; 2022 Apr; 65(7):5760-5799. PubMed ID: 35333526
[TBL] [Abstract][Full Text] [Related]
2. Discovery of Novel Phenoxyaryl Pyridones as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with High Selectivity for the Second Bromodomain (BD2) to Potentially Treat Acute Myeloid Leukemia.
Jiang W; Hou Q; Xu H; Yang K; Wang X; Zhang K; Zeng Y; Li W; Wang B; Luo G; Zhao X; Shen H; Xu Y; Wu X
J Med Chem; 2024 Jan; 67(2):1513-1532. PubMed ID: 38175809
[TBL] [Abstract][Full Text] [Related]
3. Discovery of a Bromodomain and Extra Terminal Domain (BET) Inhibitor with the Selectivity for the Second Bromodomain (BD2) and the Capacity for the Treatment of Inflammatory Diseases.
Wang Z; Yin L; Xiong Z; Huang F; Yang N; Jiang F; Li H; Cui Y; Ren J; Cheng Z; Jia K; Lu T; Zhu J; Hu Q; Chen Y
J Med Chem; 2023 Aug; 66(15):10824-10848. PubMed ID: 37478496
[TBL] [Abstract][Full Text] [Related]
4. Optimization of the synthesis of BET BD2 selective inhibitor XY153.
Zhu R; Li J; Dong R; Hu Q; Chen Z; Chen X; Zhong Z; Xiang Q; Huang C; Lin B; Wu X; Zhang Y; Zhao L; Xu Y
Chem Biodivers; 2024 Feb; 21(2):e202301584. PubMed ID: 38163253
[TBL] [Abstract][Full Text] [Related]
5. Discovery of potent BET bromodomain 1 stereoselective inhibitors using DNA-encoded chemical library selections.
Modukuri RK; Yu Z; Tan Z; Ta HM; Ucisik MN; Jin Z; Anglin JL; Sharma KL; Nyshadham P; Li F; Riehle K; Faver JC; Duong K; Nagarajan S; Simmons N; Palmer SS; Teng M; Young DW; Yi JS; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2122506119. PubMed ID: 35622893
[TBL] [Abstract][Full Text] [Related]
6. Selective inhibitors of bromodomain BD1 and BD2 of BET proteins modulate radiation-induced profibrotic fibroblast responses.
Liu CS; Rioja I; Bakr A; Veldwijk MR; Sperk E; Herskind C; Weichenhan D; Prinjha RK; Plass C; Schmezer P; Popanda O
Int J Cancer; 2022 Jul; 151(2):275-286. PubMed ID: 35239184
[TBL] [Abstract][Full Text] [Related]
7. Structure-Guided Design and Synthesis of Pyridinone-Based Selective Bromodomain and Extra-Terminal Domain (BET)-First Bromodomain (BD1) Inhibitors.
Li Y; Shen Z; Ratia K; Zhao J; Huang F; Dubrovyskyii O; Indukuri D; Fu J; Lozano Ramos O; Thatcher GRJ; Xiong R
J Med Chem; 2024 Feb; 67(4):2712-2731. PubMed ID: 38295759
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Series of
Harrison LA; Atkinson SJ; Bassil A; Chung CW; Grandi P; Gray JRJ; Levernier E; Lewis A; Lugo D; Messenger C; Michon AM; Mitchell DJ; Preston A; Prinjha RK; Rioja I; Seal JT; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
J Med Chem; 2021 Aug; 64(15):10742-10771. PubMed ID: 34232650
[TBL] [Abstract][Full Text] [Related]
9. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of bromodomain 2-specific inhibitors of BRDT.
Yu Z; Ku AF; Anglin JL; Sharma R; Ucisik MN; Faver JC; Li F; Nyshadham P; Simmons N; Sharma KL; Nagarajan S; Riehle K; Kaur G; Sankaran B; Storl-Desmond M; Palmer SS; Young DW; Kim C; Matzuk MM
Proc Natl Acad Sci U S A; 2021 Mar; 118(9):. PubMed ID: 33637650
[TBL] [Abstract][Full Text] [Related]
11. Bromodomain-Selective BET Inhibitors Are Potent Antitumor Agents against MYC-Driven Pediatric Cancer.
Slavish PJ; Chi L; Yun MK; Tsurkan L; Martinez NE; Jonchere B; Chai SC; Connelly M; Waddell MB; Das S; Neale G; Li Z; Shadrick WR; Olsen RR; Freeman KW; Low JA; Price JE; Young BM; Bharatham N; Boyd VA; Yang J; Lee RE; Morfouace M; Roussel MF; Chen T; Savic D; Guy RK; White SW; Shelat AA; Potter PM
Cancer Res; 2020 Sep; 80(17):3507-3518. PubMed ID: 32651255
[TBL] [Abstract][Full Text] [Related]
12. Discovery of the natural product 3',4',7,8-tetrahydroxyflavone as a novel and potent selective BRD4 bromodomain 2 inhibitor.
Li J; Zou W; Yu K; Liu B; Liang W; Wang L; Lu Y; Jiang Z; Wang A; Zhu J
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):903-913. PubMed ID: 33820450
[TBL] [Abstract][Full Text] [Related]
13. Structure-Guided Design of a Domain-Selective Bromodomain and Extra Terminal N-Terminal Bromodomain Chemical Probe.
Bradley E; Fusani L; Chung CW; Craggs PD; Demont EH; Humphreys PG; Mitchell DJ; Phillipou A; Rioja I; Shah RR; Wellaway CR; Prinjha RK; Palmer DS; Kerr WJ; Reid M; Wall ID; Cookson R
J Med Chem; 2023 Dec; 66(23):15728-15749. PubMed ID: 37967462
[TBL] [Abstract][Full Text] [Related]
14. Discovery of
Sheppard GS; Wang L; Fidanze SD; Hasvold LA; Liu D; Pratt JK; Park CH; Longenecker K; Qiu W; Torrent M; Kovar PJ; Bui M; Faivre E; Huang X; Lin X; Wilcox D; Zhang L; Shen Y; Albert DH; Magoc TJ; Rajaraman G; Kati WM; McDaniel KF
J Med Chem; 2020 May; 63(10):5585-5623. PubMed ID: 32324999
[TBL] [Abstract][Full Text] [Related]
15. Discovery of (R)-4-(8-methoxy-2-methyl-1-(1-phenylethy)-1H-imidazo[4,5-c]quinnolin-7-yl)-3,5-dimethylisoxazole as a potent and selective BET inhibitor for treatment of acute myeloid leukemia (AML) guided by FEP calculation.
Yu S; Zhang Y; Yang J; Xu H; Lan S; Zhao B; Luo M; Ma X; Zhang H; Wang S; Shen H; Zhang Y; Xu Y; Li R
Eur J Med Chem; 2024 Jan; 263():115924. PubMed ID: 37992518
[TBL] [Abstract][Full Text] [Related]
16. Discovery of a brain-permeable bromodomain and extra terminal domain (BET) inhibitor with selectivity for BD1 for the treatment of multiple sclerosis.
Chen X; Wu T; Du Z; Kang W; Xu R; Meng F; Liu C; Chen Y; Bao Q; Shen J; You Q; Cao D; Jiang Z; Guo X
Eur J Med Chem; 2024 Feb; 265():116080. PubMed ID: 38142510
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Benzo[
Jiang F; Hu Q; Zhang Z; Li H; Li H; Zhang D; Li H; Ma Y; Xu J; Chen H; Cui Y; Zhi Y; Zhang Y; Xu J; Zhu J; Lu T; Chen Y
J Med Chem; 2019 Dec; 62(24):11080-11107. PubMed ID: 31789032
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Benzo[d]imidazole-6-sulfonamides as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the First Bromodomain.
Cipriano A; Milite C; Feoli A; Viviano M; Pepe G; Campiglia P; Sarno G; Picaud S; Imaide S; Makukhin N; Filippakopoulos P; Ciulli A; Castellano S; Sbardella G
ChemMedChem; 2022 Oct; 17(20):e202200343. PubMed ID: 36040095
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel small molecule induced selective degradation of the bromodomain and extra-terminal (BET) bromodomain protein BRD4 and BRD2 with cellular potencies.
Jiang F; Wei Q; Li H; Li H; Cui Y; Ma Y; Chen H; Cao P; Lu T; Chen Y
Bioorg Med Chem; 2020 Jan; 28(1):115181. PubMed ID: 31767403
[TBL] [Abstract][Full Text] [Related]
20. The Optimization of a Novel, Weak Bromo and Extra Terminal Domain (BET) Bromodomain Fragment Ligand to a Potent and Selective Second Bromodomain (BD2) Inhibitor.
Seal JT; Atkinson SJ; Aylott H; Bamborough P; Chung CW; Copley RCB; Gordon L; Grandi P; Gray JRJ; Harrison LA; Hayhow TG; Lindon M; Messenger C; Michon AM; Mitchell D; Preston A; Prinjha RK; Rioja I; Taylor S; Wall ID; Watson RJ; Woolven JM; Demont EH
J Med Chem; 2020 Sep; 63(17):9093-9126. PubMed ID: 32702236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
